Overview Financials News + Filings Key Docs Charts Ownership Insiders |
BLUE CALYPSO, INC. (BCYP)
|
Add to portfolio |
|
|
Price: |
$9.97
| | Metrics |
OS: |
7.87
|
M
| |
-273
|
% ROE
|
Market cap: |
$78.5
|
M
| |
-346
|
% ROIC
|
Net cash:
|
$431.7
|
k
| |
$0.05
|
per share
|
EV:
|
$78.1
|
M
| | | |
| | | | | |
TTM Valuation | | | |
EBITDA
|
($3.0)
|
M
| |
|
|
EBIT
|
($3.4)
|
M
| |
|
|
EPS |
($0.63)
| |
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
In millions, except per share items | Dec-31-15 | Dec-31-14 | Dec-31-13 | Dec-31-12 | Sep-11-12 | Dec-31-11 | Dec-31-10 | Dec-31-09 |
Revenues | 1.0 | 0.8 | 0.3 | 0.1 | 0.1 | 0.1 | 0.0 | |
Revenue growth | 32.2% | 122.2% | 358.5% | 44.6% | | 139332.4% | | |
Cost of goods sold | 0.7 | 0.4 | 0.1 | 0.2 | 0.3 | 0.1 | 0.0 | |
Gross profit | 0.3 | 0.3 | 0.2 | -0.1 | -0.1 | -0.1 | 0.0 | |
Gross margin | 33.8% | 45.8% | 58.3% | -107.8% | -111.2% | -116.1% | 100.0% | |
Sales and marketing | 0.4 | 0.5 | 0.7 | 0.4 | 1.3 | 0.7 | 0.1 | |
General and administrative | 2.3 | 6.1 | 4.8 | 4.8 | 5.9 | 0.9 | 0.2 | |
EBITA | -2.7 | -6.6 | -5.3 | -5.3 | -8.3 | -1.7 | -0.4 | |
EBITA margin | -271.7% | -866.3% | -1559.7% | -7144.2% | -6543.1% | -3210.2% | -1005997.3% | |
Amortization of intangibles | | | 0.3 | 0.2 | | 0.1 | | |
EBIT | -2.7 | -6.6 | -5.6 | -5.6 | -8.3 | -1.8 | -0.4 | |
EBIT margin | -271.7% | -866.3% | -1645.8% | -7447.9% | -6543.1% | -3445.4% | -1005997.3% | |
Pre-tax income | -3.3 | -7.7 | -6.8 | -5.1 | -17.6 | -12.1 | -0.4 | |
Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
Net income | -3.3 | -7.7 | -6.8 | -5.1 | -17.6 | -12.1 | -0.4 | |
Net margin | -328.8% | -1018.0% | -1995.4% | -6805.3% | -13951.2% | -23492.2% | -1051445.9% | |
|
Diluted EPS | ($0.65) | ($1.80) | ($0.05) | ($0.04) | | ($0.13) | ($0.01) | |
Shares outstanding (diluted) | 5.1 | 4.3 | 144.3 | 133.1 | | 90.8 | 56.4 | |
|
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|